Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | GABRE | P78334 | 2/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407967 | 1.00 | PPARA (0.46) | PPARAACHEBACE1GABRPGABRD | |
| SCHEMBL6866865 | 1.00 | PPARA (0.46) | PPARAACHEBACE1GABRPGABRD | |
| SCHEMBL5568055 | 1.00 | PPARA (0.46) | PPARAACHEBACE1GABRPGABRD | |
| SCHEMBL13604722 | 0.84 | CNR2 (0.38) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL12973059 | 0.83 | — | — | |
| SCHEMBL15353 | 0.83 | — | — | |
| SCHEMBL15352 | 0.83 | — | — | |
| SCHEMBL17866776 | 0.83 | PPARA (0.43) | PPARAACHEBACE1GABRPGABRD | |
| SCHEMBL9446902 | 0.83 | PPARA (0.43) | PPARAACHEBACE1GABRPGABRD | |
| SCHEMBL17866774 | 0.83 | PPARA (0.43) | PPARAACHEBACE1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-108699098-B | C-glucoside derivative having fused benzene ring or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition comprising same | 第一药品株式会社 | 2022-01-25 | — | — | CN | disclosed |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. (KR) | 2020-08-25 | — | — | US | disclosed |
| EP-3404033-B1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2020-08-05 | — | — | EP | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190002425-A1 | C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2019-01-03 | — | — | US | disclosed |
| EP-3404033-A1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2018-11-21 | — | — | EP | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20050287641-A1 | Nucleotide sequences coding polypeptide for use in generation of preferential antibiotics; polynucleotide which encodes a domain of a ramoplanin nonribosomal peptide synthetase | ECOPIA BIOSCIENCES, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050106691-A1 | Process for the production of ramoplanin-like amide derivatives | VICURON PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1326983-B1 | GENE CLUSTER FOR RAMOPLANIN BIOSYNTHESIS | ECOPIA BIOSCIENCES INC (CA) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005010117-A1 | CLING ARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050000642-A1 | Cling articles | 3M INNOVATIVE PROPERTIES COMPANY | 2005-01-06 | — | — | US | disclosed |
| EP-1483286-A1 | A PROCESS FOR THE PRODUCTION OF RAMOPLANIN-LIKE AMIDE DERIVATIVES | Vicuron Pharmaceuticals, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076460-A1 | A PROCESS FOR THE PRODUCTION OF RAMOPLANIN-LIKE AMIDE DERIVATIVES | VICURON PHARMACEUTICALS INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| EP-1326983-A2 | GENE CLUSTER FOR RAMOPLANIN BIOSYNTHESIS | Ecopia Biosciences Inc. (CA) | 2003-07-16 | — | — | EP | disclosed |
| US-20020164747-A1 | Gene cluster for ramoplanin biosynthesis | ECOPIA BIOSCIENCES INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002031155-A2 | GENE CLUSTER FOR RAMOPLANIN BIOSYNTHESIS | ECOPIA BIOSCIENCES INC. (CA) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002425-A1 | C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, UGGT1 | PPARA 615/4885ACHE 3857/4885BACE1 3374/4885 |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | SLC5A2, SLC5A1, UGGT1 | PPARA 615/4885ACHE 3857/4885BACE1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.